Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S. Yamada Y, et al. Among authors: shimada y. Br J Cancer. 2003 Sep 1;89(5):816-20. doi: 10.1038/sj.bjc.6601224. Br J Cancer. 2003. PMID: 12942110 Free PMC article.
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K. Matsumura Y, et al. Among authors: shimada y. Ann Oncol. 2004 Mar;15(3):517-25. doi: 10.1093/annonc/mdh092. Ann Oncol. 2004. PMID: 14998859 Free article. Clinical Trial.
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Matsubara J, et al. Among authors: shimada y. Br J Cancer. 2008 Feb 26;98(4):832-9. doi: 10.1038/sj.bjc.6604211. Epub 2008 Jan 29. Br J Cancer. 2008. PMID: 18231104 Free PMC article.
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Horita Y, Yamada Y, Hirashima Y, Kato K, Nakajima T, Hamaguchi T, Shimada Y. Horita Y, et al. Among authors: shimada y. Cancer Chemother Pharmacol. 2010 Feb;65(3):467-71. doi: 10.1007/s00280-009-1051-4. Epub 2009 Jun 25. Cancer Chemother Pharmacol. 2010. PMID: 19554330 Clinical Trial.
3,643 results